227 related articles for article (PubMed ID: 1576351)
1. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
Abdel-Nabi HH; Doerr RJ
Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
[TBL] [Abstract][Full Text] [Related]
2. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
[TBL] [Abstract][Full Text] [Related]
3. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
Doerr RJ; Herrera L; Abdel-Nabi H
Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
[TBL] [Abstract][Full Text] [Related]
4. Results of immunoscintigraphy using a cocktail of radiolabeled monoclonal antibodies in the detection of colorectal cancer.
Volpe CM; Abdel-Nabi HH; Kulaylat MN; Doerr RJ
Ann Surg Oncol; 1998 Sep; 5(6):489-94. PubMed ID: 9754756
[TBL] [Abstract][Full Text] [Related]
5. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
[TBL] [Abstract][Full Text] [Related]
6. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?
Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP
Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800
[TBL] [Abstract][Full Text] [Related]
7. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
[TBL] [Abstract][Full Text] [Related]
8. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunodetection of colorectal carcinoma.
Artiko V; Obradovic V; Davidovic B; Petrovic N; Petrovic M; Krivokapic Z; Kecmanovic D; Pesko P; Djukic V; Milosavljevic T; Adanja G; Vlajkovic M
Hepatogastroenterology; 2003; 50(52):1029-31. PubMed ID: 12845972
[TBL] [Abstract][Full Text] [Related]
10. Immunoscintigraphy of primary colorectal cancers with indium-111 monoclonal antibody B72.3.
Joypaul BV; Kennedy N; Hanson J; Holley M; Browning M; Newman EL; Cuschieri A
J R Coll Surg Edinb; 1994 Feb; 39(1):39-43. PubMed ID: 7515429
[TBL] [Abstract][Full Text] [Related]
11. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma.
Markowitz A; Saleemi K; Freeman LM
Clin Nucl Med; 1993 Aug; 18(8):685-700. PubMed ID: 8403703
[TBL] [Abstract][Full Text] [Related]
12. Immunoscintigraphy of colorectal carcinoma utilizing 111In-labeled monoclonal antibody conjugate CYT-103.
Neal CE; Swan TL; Baker MR; Ellis RL; Katterhagen JG
Gastrointest Radiol; 1991; 16(3):251-5. PubMed ID: 1879645
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
14. [Indium 111-labeled antibodies in the detection of colorectal carcinoma].
Artiko V; Obradović V; Davidović B; Petrović N; Petrović M; Krivokapić Z; Pavlov M; Adanja G; Sobić D; Vlajković M; Pavlović S; Rebić R
Acta Chir Iugosl; 2003; 50(4):43-6. PubMed ID: 15307496
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis.
Corbisiero RM; Yamauchi DM; Williams LE; Esteban JM; Odom-Maryon T; Beatty JD
Cancer Res; 1991 Oct; 51(20):5704-11. PubMed ID: 1913688
[TBL] [Abstract][Full Text] [Related]
16. Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management.
Corman ML; Galandiuk S; Block GE; Prager ED; Weiner GJ; Kahn D; Abdel-Nabi H; Mitchell EP; Pascucci VL; Maroli AN
Dis Colon Rectum; 1994 Feb; 37(2):129-37. PubMed ID: 8306832
[TBL] [Abstract][Full Text] [Related]
17. Use of OncoScint scan to assess resectability of hepatic metastases from colorectal cancer.
Su WT; Brachman M; O'Connell TX
Am Surg; 2001 Dec; 67(12):1200-3. PubMed ID: 11768830
[TBL] [Abstract][Full Text] [Related]
18. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates.
Maguire RT; Pascucci VL; Maroli AN; Gulfo JV
Cancer; 1993 Dec; 72(11 Suppl):3453-62. PubMed ID: 8242578
[TBL] [Abstract][Full Text] [Related]
19. OncoScint CR103 imaging in the surgical management of patients with colorectal cancer.
Doerr RJ; Abdel-Nabi HH
Targeted Diagn Ther; 1992; 6():89-109. PubMed ID: 1576352
[No Abstract] [Full Text] [Related]
20. Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study.
Doerr RJ; Abdel-Nabi H; Krag D; Mitchell E
Ann Surg; 1991 Aug; 214(2):118-24. PubMed ID: 1867518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
